{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:39:19Z","timestamp":1770799159626,"version":"3.50.0"},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2020,8,20]]},"abstract":"<jats:sec><jats:title\/><jats:p>Lymphoma refers to a specialized category of blood cancers, which is characterized by lymph node enlargement, reduced body weight, prolonged tiredness, and fever associated with sweats. Traditional treatment strategies involve chemotherapy, radiation therapy, targeted therapy, and surgery. Copanlisib has emerged as a very potent drug which acts through inhibiting PI3K enzyme. The FDA has approved it for specific treatment of follicular Lymphoma in September 2017. Copanlisib induces tumor cell death along with the prevention of proliferation of dominant malignant &amp;#946;-cells. Copanlisib has a large volume of distribution i.e., 871L (%CV 47.4), plasma protein binding up to 15.8%, plasma half-life(t1\/2) of 39.1h and the mean systemic plasma clearance 18.9 L\/h (%CV 51.2). In the present review, various aspects related to Copanlisib have been summarized, which include pathophysiology, synthetic strategy, pharmacokinetics, pharmacodynamics and clinical studies. A special emphasis is paid on various reported adverse effects and in silico\/in vivo studies conducted on Copanlisib.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871520620666200317105207","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T14:24:41Z","timestamp":1584455081000},"page":"1158-1172","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma"],"prefix":"10.2174","volume":"20","author":[{"given":"Anshul","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry & Analysis, Indo-Soviet Friendship College of Pharmacy, Ferozepur G.T. Road, Moga-142 001, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry & Analysis, Indo-Soviet Friendship College of Pharmacy, Ferozepur G.T. Road, Moga-142 001, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Chawla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry & Analysis, Indo-Soviet Friendship College of Pharmacy, Ferozepur G.T. Road, Moga-142 001, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Durgadas","family":"Anghore","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry & Analysis, Indo-Soviet Friendship College of Pharmacy, Ferozepur G.T. Road, Moga-142 001, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipin","family":"Saini","sequence":"additional","affiliation":[{"name":"Maharishi Markandeshwar University, Solan-173229, Himachal Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravindra K.","family":"Rawal","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Maharishi Markandeshwar (Deemed to be University), Mullana-133207, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","author":"Taylor,E. .J","unstructured":"Taylor.; E.J. Dorland\u2019s illustrated medical dicti onary, 29th ed; Saunders: Philadelphia. 2000."},{"key":"ref=2","author":"Bower,M. .","unstructured":"Bower,M.; Waxman, J. Lecture Notes: Oncology, 2nd ed; Wiley-Blackwell: United States. 2011"},{"key":"ref=3","unstructured":"SEER Stat Fact Sheets: Hodgkin Lymphoma. NCI. 2016 April; Archived from the original on 17 October 2012. Retrieved 13 August 2016"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","volume":"27(10)","author":"Patnaik,A.","year":"2016","unstructured":"Patnaik,A.; Appleman, L.J.; Tolcher, A.W.; Papadopoulos, K.P.; Beeram,M.; Rasco, D.W.; Weiss, G.J.; Sachdev, J.C.; Chadha,M.; Fulk,M.; Ejadi,S.; Mountz, J.M.; Lotze, M.T.; Toledo, F.G.; Chu,E.; Jeffers,M.; Pe\u00f1a,C.; Xia,C.; Reif,S.; Genvresse,I.; Ramana-than, R.K. First-in-human phase I study of copanlisib (BAY 80-6946),an intravenous pan-class I p hosphatidylinositol 3-kinase in-hibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas. Ann. Oncol. 2016,27(10),1928-1940. http:\/\/dx.doi.org\/10.1093\/annonc\/mdw282 PMID: 27672108","journal-title":"Ann.Oncol"},{"key":"ref=5","first-page":"14","volume":"2014(12)","author":"Dreyling,M.","year":"2014","unstructured":"Dreyling,M.; Morschhauser,F.; Bron,D.; Bouabdallah,K.; Vitolo,M.; Linton, K. Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3 K inhibitor, in patients with re-lapsed\/refractory, indolent or aggressive lymphoma. Clin. Adv. Hematol. Oncol. 2014,2014(12),14-16","journal-title":"Clin.Adv..Hematol.Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110 807.092311","volume":"4","author":"Chalhoub,N.","year":"2009","unstructured":"Chalhoub,N.; Baker, S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009,4,127-150. http:\/\/dx.doi.org\/10.1146\/annurev.pathol.4.110 807.092311 PMID: 18767981","journal-title":"Annu.Rev.Pathol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/CCO.0000000000000113","volume":"26(5)","author":"Curran,E.","year":"2014","unstructured":"Curran,E.; Smith, S.M. Phosphoinos itide 3-kinase inhibitors in lymphoma. Curr. Opin. Oncol. 2014,26(5),469-475. http:\/\/dx.doi.org\/10.1097\/CCO.0000000000000113 PMID: 25024054","journal-title":"Curr.Opin.Oncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/leu.2015.105","volume":"29(9)","author":"Bala,Krishnan,K","year":"2015","unstructured":"Bala Krishnan,K.; Peluso,M.; Fu,M.; Rosin, N.Y.; Burger, J.A.; Wierda, W.G.; Keating, M.J. The phosphoinos itide-3-kinase (PI3 K)-delta and gamma inhibitor, IPI-145 (Duvelisib),overcomes sig-nals from the PI3 K\/ AKT\/S6 pathway and promotes apoptosis in CLL. Leukaemia. 2015,29(9),1811-1822. http:\/\/dx.doi.org\/10.1038\/leu.2015.105","journal-title":"Leukaemia"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1158\/1078-0432.CCR-11-1402","volume":"18(15)","author":"Herman, S.E.","year":"2012","unstructured":"Herman, S.E.; Johnson, A.J. Molecular pathways: Targeting phos-phoinositide 3-kinase p110-delta in chronic lymphocytic leukemi a. Clin. Cancer Res. 2012,18(15),4013-4018. http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-11-1402 PMID: 22711705","journal-title":"Clin.Cancer Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/cmdc.201600148","volume":"11(14)","author":"Scott, W.J.","year":"2016","unstructured":"Scott, W.J.; Hentemann, M.F.; Rowley, R.B.; Bull, C.O.; Jenkins,S.; Bullion, A.M.; Johnson,J.; Redman,A.; Robbins, A.H.; Esler,W.; Fracasso, R.P.; Garrison,T.; Hamilton,M.; Michels,M.; Wood, J.E.; Wilkie, D.P.; Xiao,H.; Levy,J.; Stasik,E.; Liu,N.; Schaefer,M.; Brands,M.; Lefranc, J. Discovery and SAR of novel 2,3-Dihydroimidazo[1,2-c] quinazoline PI3 K inhibitors: Identifica-tion of copanlisib (BAY 80-6946) . ChemMedChem. 2016,11(14),1517-1530. http:\/\/dx.doi.org\/10.1002\/cmdc.201600148 PMID: 27310202","journal-title":"ChemMedChem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","volume":"12(11)","author":"Liu,N.","year":"2013","unstructured":"Liu,N.; Rowley, B.R.; Bull, C.O.; Schneider,C.; Haegebarth,A.; Schatz, C.A.; Fracasso, P.R.; Wilkie, D.P.; Hentemann,M.; Wil-helm, S.M.; Scott, W.J.; Mumberg,D.; Ziegelbauer, K. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110a and p110d activ ities in tumor cell lines and xenograft mod-els. Mol. Cancer Ther. 2013,12(11),2319-2330. http:\/\/dx.doi.org\/10.1158\/1535-7163.MCT-12-0993-T PMID: 24170767","journal-title":"Mol.Cancer Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00280-016-3198-0","volume":"79(1)","author":"Doi,T.","year":"2017","unstructured":"Doi,T.; Fuse,N.; Yoshino,T.; Kojima,T.; Bando,H.; Miyamoto,H.; Kaneko,M.; Osada,M.; Ohtsu, A. A Phase I study of intrave-nous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. Cancer Chemother. Pharmacol. 2017,79(1),89-98. http:\/\/dx.doi.org\/10.1007\/s00280-016-3198-0 PMID: 27915408","journal-title":"Cancer Chemother.Pharmacol"},{"key":"ref=13","first-page":"186","volume":"33(3)","author":"Guilherme, R.S.","year":"2008","unstructured":"Guilherme, R.S.; Caputto, L.Z.; Fonseca, A.L.; Pereira,J.; Fonseca, F.L. Exames laboratoriais complementares indicados no apoio ao diagn\u00f3stico do Linfoma Difuso de Grandes C\u00e9lulas B (LDGCB) . Arq Bras Ci\u00eanc. Sa\u00fade. 2008,33(3),186-194","journal-title":"Arq Bras Ci\u00eanc..Sa\u00fade"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","volume":"127(17)","author":"Kahl, B.S.","year":"2016","unstructured":"Kahl, B.S.; Yang, D.T. Follicular lymphoma: Evolving therapeutic strategies. Blood. 2016,127(17),2055-2063. http:\/\/dx.doi.org\/10.1182\/blood-2015-11-624288 PMID: 26989204","journal-title":"Blood"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.32635\/2176-9745.RBC.2001v47n3.2308","volume":"43(3)","author":"Klumb,C.E","year":"2001","unstructured":"Klumb.; C.E. Biology and pathogenesis on non-Hodgkin\u2019s Lym-phomas of B origin in childhood: A review. Rev. Bras. Cancerol. 2001,43(3),291-301","journal-title":"Rev.Bras..Cancerol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296(5573)","author":"Cantley,L.C","year":"2002","unstructured":"Cantley.; L.C. The phosphoinos itide 3-kinase path way. Science. 2002,296(5573),1655-1657. http:\/\/dx.doi.org\/10.1126\/science.296.5573.1655 PMID: 12040186","journal-title":"Science"},{"key":"ref=17","author":"Vanhaesebroeck,B.","unstructured":"Vanhaesebroeck,B.; Whitehead, M.A.; Pi\u00f1eiro, R. Molecules in medicine mini-review: Isoforms of PI3K in biology and disease, J. Mol. Med. (Berl.),2016,94(1),5-11. http:\/\/dx.doi.org\/10.1007\/s00109-015-1352-5 PMID: 26658520","journal-title":"Mol.Med.(Berl."},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pharmthera.2014.09.006","volume":"146","author":"Bauer, T.M.","year":"2015","unstructured":"Bauer, T.M.; Patel, M.R.; Infante, J.R. Targeting PI3 kinase in cancer. Pharmacol. Ther. 2015,146,53-60. http:\/\/dx.doi.org\/10.1016\/j.pharmthera.2014.09.006 PMID: 25240910","journal-title":"Pharmacol.Ther"},{"key":"ref=19","author":"Shimada,M.","unstructured":"Shimada,M.; Murata,T.; Fuchikami,K.; Tsujishita,H.; Omori,N.; Kato, I. Fused azole-pyrimidine derivatives (Bayer Pharmaceuti-cals Corp.) . WO 2004029055 (20030918),2004","journal-title":"WO 2004029055 (20030918),2004"},{"key":"ref=20","unstructured":"https:\/\/www.drugbank.ca\/drugs\/DB12483 Mechanism of action of copanlisib"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","volume":"30(23)","author":"Busaidy, N.L.","year":"2012","unstructured":"Busaidy, N.L.; Farooki,A.; Dowlati,A.; Perentesis, J.P.; Dancey, J.E.; Doyle, L.A.; Brell, J.M.; Siu, L.L. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway, J. Clin. Oncol. 2012,30(23),2919-2928. http:\/\/dx.doi.org\/10.1200\/JCO.2011.39.7356 PMID: 22778315","journal-title":"Clin.Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369(1)","author":"Byrd, J.C.","year":"2013","unstructured":"Byrd, J.C.; Furman, R.R.; Coutre, S.E.; Flinn, I.W.; Burger, J.A.; Blum, K.A.; Grant,B.; Sharman, J.P.; Coleman,M.; Wierda, W.G.; Jones, J.A.; Zhao,W.; Heerema, N.A.; Johnson, A.J.; Suk-buntherng,J.; Chang, B.Y.; Clow,F.; Hedrick,E.; Buggy, J.J.; James, D.F.; O\u2019Brien, S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia, N. Engl, J. Med. 2013,369(1),32-42. http:\/\/dx.doi.org\/10.1056\/NEJMoa1215637 PMID: 23782158","journal-title":"Engl, J.Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1681\/ASN.2006050541","volume":"18(3)","author":"Quaschning,T.","year":"2007","unstructured":"Quaschning,T.; Voss,F.; Relle,K.; Kalk,P.; Vignon-Zellweger,N.; Pfab,T.; Bauer,C.; Theilig,F.; Bachmann,S.; Kr aemer-Guth,A.; Wanner,C.; Theuring,F.; Galle,J.; Hocher, B. Lack of endo-thelial nitric oxide synthase promotes endothelin-induced hyperten-sion: lessons from endothelin-1 transgenic\/endothelial nitric oxide synthase knockout mice, J. Am. Soc. Nephrol. 2007,18(3),730-740. http:\/\/dx.doi.org\/10.1681\/ASN.2006050541 PMID: 17287431","journal-title":"Am.Soc.Nephrol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370(11)","author":"Gopal, A.K.","year":"2014","unstructured":"Gopal, A.K.; Kahl, B.S.; de Vos,S.; Wagner-Johnston, N.D.; Schuster, S.J.; Jurczak, W.J.; Flinn, I.W.; Flowers, C.R.; Martin,P.; Viardot,A.; Blum, K.A.; Goy, A.H.; Davies, A.J.; Zinzani, P.L.; Dreyling,M.; Johnson,D.; Miller, L.L.; Holes,L.; Li,D.; Dansey, R.D.; Godfrey, W.R.; Salles, G.A. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma, N. Engl, J. Med. 2014,370(11),1008-1018. http:\/\/dx.doi.org\/10.1056\/NEJMoa1314583 PMID: 24450858","journal-title":"Engl, J.Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30(3)","author":"Bendell, J.C.","year":"2012","unstructured":"Bendell, J.C.; Rodon,J.; Burris, H.A.; de Jonge,M.; Verweij,J.; Birle,D.; Demanse,D.; De Buck, S.S.; Ru, Q.C.; Peters,M.; Gold-brunner,M.; Baselga, J. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with ad-vanced solid tumors, J. Clin. Oncol. 2012,30(3),282-290. http:\/\/dx.doi.org\/10.1200\/JCO.2011.36.1360 PMID: 22162589","journal-title":"Clin.Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-14-1306","volume":"21(8)","author":"Shapiro, G.I.","year":"2015","unstructured":"Shapiro, G.I.; Bell-McGuinn, K.M.; Molina, J.R.; Bendell,J.; Spicer,J.; Kwak, E.L.; Pandya, S.S.; Millham,R.; Borz-illo,G.; Pierce, K.J.; Han,L.; Houk, B.E.; Gallo, J.D.; Alsina,M.; Bra\u00f1a,I.; Tabernero, J. First-the human study of PF-05212384 (PKI-587),a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin. Cancer Res. 2015,21(8),1888-1895. http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-14-1306 PMID: 25652454","journal-title":"Clin.Cancer Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123(22)","author":"Flinn, I.W.","year":"2014","unstructured":"Flinn, I.W.; Kahl, B.S.; Leonard, J.P.; Furman, R.R.; Brown, J.R.; Byrd, J.C.; Wagner-Johnston, N.D.; Coutre, S.E.; Benson, D.M.; Peterman,S.; Cho,Y.; Webb, H.K.; Johnson, D.M.; Yu, A.S.; Ul-rich, R.G.; Godfrey, W.R.; Miller, L.L.; Spurgeon, S.E. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014,123(22),3406-3413. http:\/\/dx.doi.org\/10.1182\/blood-2013-11-538546 PMID: 24615776","journal-title":"Blood"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","volume":"29(35)","author":"Yap, T.A.","year":"2011","unstructured":"Yap, T.A.; Yan,L.; Patnaik,A.; Fearen,I.; Olmos,D.; Papadopou-los,K.; Baird, R.D.; Delgado,L.; Taylor,A.; Lupinacci,L.; Riis-naes,R.; Pope, L.L.; Heaton, S.P.; Thomas,G.; Garrett, M.D.; Sul-livan, D.M.; de Bono, J.S.; Tolcher, A.W. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors, J. Clin. Oncol. 2011,29(35),4688-4695. http:\/\/dx.doi.org\/10.1200\/JCO.2011.35.5263 PMID: 22025163","journal-title":"Clin.Oncol"},{"key":"ref=29","author":"Britten, C.D.","unstructured":"Britten, C.D.; Adjei, A.A.; Millham,R.; Houk, B.E.; Borzillo,G.; Pierce,K.; Wainberg, Z.A.; LoRusso, P.M. Phase I study of PF-"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","volume":"125(4)","author":"Knight, Z.A.","year":"2006","unstructured":"Knight, Z.A.; Gonzalez,B.; Feldman, M.E.; Zunder, E.R.; Golden-berg, D.D.; Williams,O.; Loewith,R.; Stokoe,D.; Balla,A.; Toth,B.; Balla,T.; Weiss, W.A.; Williams, R.L.; Shokat, K.M. A phar-macological map of the PI3-K family defines a role for p110a in insulin signaling. Cell. 2006,125(4),733-747. http:\/\/dx.doi.org\/10.1016\/j.cell.2006.03.035 PMID: 16647110","journal-title":"Cell"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1158\/1078-0432.CCR-14-3262","volume":"21(14)","author":"Brown, J.R.","year":"2015","unstructured":"Brown, J.R.; Davids, M.S.; Rodon,J.; Abrisqueta,P.; Kasar, S.N.; Lager,J.; Jiang,J.; Egile,C.; Awan, F.T. Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408\/XL147) in patients with Chronic Lymphocytic Leukemia (CLL) or relapsed\/refractory lym-phoma. Clin. Cancer Res. 2015,21(14),3160-3169. http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-14-3262 PMID: 25840972","journal-title":"Clin.Cancer Res"},{"key":"ref=32","author":"Sarker,D.","unstructured":"Sarker,D.; Ang, J.E.; Baird,R.; Kristeleit,R.; Shah,K.; Moreno,V.; Clarke, P.A.; Raynaud, F.I.; Levy,G.; Ware, J.A.; Mazina,K.; Lin,R.; Wu,J.; Fredrickson,J.; Spoerke, J.M.; Lackner, M.R.; Yan,Y.; Friedman, L.S.; Kaye, S.B.; Derynck, M.K.; Workman,P.; de Bono, J.S. First-in-human phase I study of pic tilisib (GDC-"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/CIRCRESAHA.108.189316","volume":"104(9)","author":"Symons, J.D.","year":"2009","unstructured":"Symons, J.D.; McMillin, S.L.; Riehle,C.; Tanner,J.; Palionyte,M.; Hillas,E.; Jones,D.; Cooksey, R.C.; Bir-nbaum, M.J.; McClain, D.A.; Zhang, Q.J.; Gale,D.; Wilson, L.J.; Abel, E.D. Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure. Circ. Res. 2009,104(9),1085-1094. http:\/\/dx.doi.org\/10.1161\/CIRCRESAHA. 108.189316 PMID: 19342603","journal-title":"Circ.Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21(8)","author":"Wilson, W.H.","year":"2015","unstructured":"Wilson, W.H.; Young, R.M.; Schmitz,R.; Yang,Y.; Pittaluga,S.; Wright,G.; Lih, C.J.; Williams, P.M.; Shaffer, A.L.; Gerecitano,J.; de Vos,S.; Goy,A.; Kenkre, V.P.; Barr, P.M.; Blum, K.A.; Shus-tov,A.; Advani,R.; Fowler, N.H.; Vose, J.M.; Elstrom, R.L.; Habermann, T.M.; Barrientos, J.C.; McGreivy,J.; Fardis,M.; Chang, B.Y.; Clow,F.; Munneke,B.; Moussa,D.; Beaupre, D.M.; Staudt, L.M. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 2015,21(8),922-926. http:\/\/dx.doi.org\/10.1038\/nm.3884 PMID: 26193343","journal-title":"Nat.Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","volume":"130(3)","author":"Erdmann,T.","year":"2017","unstructured":"Erdmann,T.; Klener,P.; Lynch, J.T.; Grau,M.; Vock ov\u00e1, P.; Molinsky,J.; Tuskova,D.; Hudson,K.; Polanska, U.M.; Grondine,M.; Mayo,M.; Dai,B.; Pfeifer,M.; Erdmann,K.; Schwammbach,D.; Zapukhlyak,M.; Staiger, A.M.; Ott,G.; Berdel, W.E.; Davies, B.R.; Cruzalegui,F.; Trneny,M.; Lenz,P.; Barry, S.T.; Lenz, G. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017,130(3),310-322. http:\/\/dx.doi.org\/10.1182\/blood-2016-12-758599 PMID: 28202458","journal-title":"Blood"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","volume":"31(1)","author":"Paul,J.","year":"2017","unstructured":"Paul,J.; Soujon,M.; Wengner, A.M.; Zitzmann-Kolbe,S.; Sturz,A.; Haike,K.; Keng Magdalene, K.H.; Tan, S.H.; Lange,M.; Tan, S.Y.; Mumberg,D.; Lim, S.T.; Ziegelbauer,K.; Liu, N. Simultane-ous inhibition of PI3Kd and PI3Ka induces ABCDLBCL regres-sion by blocking BCR-dependent and-independent activation of NF-?B and AKT. Cancer Cell. 2017,31(1),64-78. http:\/\/dx.doi.org\/10.1016\/j.ccell.2016.12.003 PMID: 28073005","journal-title":"Cancer Cell"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123(22)","author":"Kahl, B.S.","year":"2014","unstructured":"Kahl, B.S.; Spurgeon, S.E.; Furman, R.R.; Flinn, I.W.; Coutre, S.E.; Brown, J.R.; Benson, D.M.; Byrd, J.C.; Peterman,S.; Cho,Y.; Yu,A.; Godfrey, W.R.; Wagner-Johnston, N.D. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with re-lapsed\/refractory mantle cell lymphoma (MCL) . Blood. 2014,123(22),3398-3405. http:\/\/dx.doi.org\/10.1182\/blood-2013-11-537555 PMID: 24615778","journal-title":"Blood"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126(6)","author":"Wang, M.L.","year":"2015","unstructured":"Wang, M.L.; Blum, K.A.; Martin,P.; Goy,A.; Auer,R.; Kahl, B.S.; Jurczak,W.; Advani, R.H.; Romaguera, J.E.; Williams, M.E.; Barrientos, J.C.; Chmielowska,E.; Radford,J.; Stilgenbauer,S.; Dreyling,M.; Jedrzejczak, W.W.; Johnson,P.; Spurgeon, S.E.; Zhang,L.; Baher,L.; Cheng,M.; Lee,D.; Beaupre, D.M.; Rule, S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood. 2015,126(6),739-745. http:\/\/dx.doi.org\/10.1182\/blood-2015-03-635326 PMID: 26059948","journal-title":"Blood"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","volume":"121(12)","author":"Iyengar,S.","year":"2013","unstructured":"Iyengar,S.; Clear,A.; B\u00f6d\u00f6r,C.; Maharaj,L.; Lee,A.; Calaminici,M.; Matthews,J.; Iqbal,S.; Auer,R.; Gribben,J.; Joel, S. P110a-mediated constitutive PI3K signaling limits the efficacy of p110d-selective inhibition in mantle cell lymphoma, particularly with mul-tiple relapse. Blood. 2013,121(12),2274-2284. http:\/\/dx.doi.org\/10.1182\/blood-2012-10-460832 PMID: 23341541","journal-title":"Blood"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1182\/blood.V124.21.803.803","volume":"124","author":"Horwitz, S.M.","year":"2014","unstructured":"Horwitz, S.M.; Porcu,P.; Flinn, I. Duvelisib (IPI-145),a phosphoi-nositide-3-kinase-d, ? inhibitor, shows activity in patients with re-lapsed\/refractory T-cell lymphoma. Blood ASH Annual Meeting Abstracts. 2014,124,803. http:\/\/dx.doi.org\/10.1182\/blood.V124.21.803.803","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.seminoncol.2016.11.011","volume":"43(6)","author":"Pongas,G.","year":"2016","unstructured":"Pongas,G.; Cheson, B.D. PI3K signaling pathway in normal B cells and indolent B-cell malignancies. Semin. Oncol. 2016,43(6),647-654. http:\/\/dx.doi.org\/10.1053\/j.seminoncol.2016.11.011 PMID: 28061982","journal-title":"Semin.Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1158\/1078-0432.CCR-08-1253","volume":"15(1)","author":"Crouthamel, M.C.","year":"2009","unstructured":"Crouthamel, M.C.; Kahana, J.A.; Korenchuk,S.; Zhang, S.Y.; Sundaresan,G.; Eberwein, D.J.; Brown, K.K.; Kumar, R. Mecha-nism and management of AKT inhibitor-induced hyperglycemia. Clin. Cancer Res. 2009,15(1),217-225. http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-08-1253 PMID: 19118049","journal-title":"Clin.Cancer Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(16) 30671-4","volume":"18(3)","author":"Zelenetz, A.D.","year":"2017","unstructured":"Zelenetz, A.D.; Barrientos, J.C.; Brown, J.R.; Coiffier,B.; Del-gado,J.; Egyed,M.; Ghia,P.; Ill\u00e9s, \u00c1.; Jurczak,W.; Marlton,P.; Montillo,M.; Morschhauser,F.; Pristupa, A.S.; Robak,T.; Shar-man, J.P.; Simpson,D.; Smolej,L.; Tausch,E.; Adewoye, A.H.; Dreiling, L.K.; Kim,Y.; Stilgenbauer,S.; Hillmen, P. Idelalisib or placebo in combination with bendamustine and rituximab in pa-tients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017,18(3),297-311. http:\/\/dx.doi.org\/10.1016\/S1470-2045(16) 30671-4 PMID: 28139405","journal-title":"Lancet Oncol"},{"key":"ref=44","author":"U. .S","unstructured":"U.S. Food and Drug Administration. FDA alerts healthcare profes-sionals about clinical trials with Zydelig (idelalisib) in combination with other cancer medicines"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56(10)","author":"Coutr\u00e9, S.E.","year":"2015","unstructured":"Coutr\u00e9, S.E.; Barrientos, J.C.; Brown, J.R.; de Vos,S.; Furman, R.R.; Keating, M.J.; Li,D.; O\u2019Brien, S.M.; Pagel, J.M.; Poleski, M.H.; Sharman, J.P.; Yao, N.S.; Zelenetz, A.D. Management of adverse events associated with idelalisib treatment: Expert panel opinion. Leuk. Lymphoma. 2015,56(10),2779-2786. http:\/\/dx.doi.org\/10.3109\/10428194.2015.1022770 PMID: 25726955","journal-title":"Leuk.Lymphoma"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","volume":"39(12)","author":"Weidner, A.S.","year":"2015","unstructured":"Weidner, A.S.; Panarelli, N.C.; Geyer, J.T.; Bhavsar, E.B.; Furman, R.R.; Leonard, J.P.; Jessurun,J.; Yantiss, R.K. Idelalisib-associated colitis: histologic findings in 14 patients. Am, J. Surg. Pathol. 2015,39(12),1661-1667. http:\/\/dx.doi.org\/10.1097\/PAS.0000000000000522 PMID: 26448188","journal-title":"Am, J.Surg.Pathol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/PDM.0b013e31815d0588","volume":"17(3)","author":"Baohua,Y.","year":"2008","unstructured":"Baohua,Y.; Xiaoyan,Z.; Tiecheng,Z.; Tao,Q.; Daren, S. Muta-tions of the PIK3CA gene in diffuse large B cell lymphoma. Diagn. Mol. Pathol. 2008,17(3),159-165. http:\/\/dx.doi.org\/10.1097\/PDM.0b013e31815d0588 PMID: 18382359","journal-title":"Diagn.Mol.Pathol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/10428190902803651","volume":"50(5)","author":"Marincevic,M.","year":"2009","unstructured":"Marincevic,M.; Tobin,G.; Rosenquist, R. Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia. Leuk. Lym-phoma. 2009,50(5),829-830. http:\/\/dx.doi.org\/10.1080\/10428190902803651 PMID: 19330652","journal-title":"Leuk.Lym-phoma"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1124\/dmd.111.039339","volume":"39(8)","author":"Graham, R.A.","year":"2011","unstructured":"Graham, R.A.; Lum, B.L.; Morrison,G.; Chang,I.; Jorga,K.; Dean,B.; Shin, Y.G.; Yue,Q.; Mulder,T.; Malhi,V.; Xie,M.; Low, J.A.; Hop, C.E. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab. Dispos. 2011,39(8),1460-1467. http:\/\/dx.doi.org\/10.1124\/dmd.111.039339 PMID: 21602311","journal-title":"Drug Metab.Dispos"},{"key":"ref=50","unstructured":"https:\/\/www.accessdata.fda.gov\/drug satfda_docs\/label\/2017\/209936s000lbl.pdf Pharmacokinetic of copanlisib"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/03602530600952172","volume":"39(1)","author":"Roffey, S.J.","year":"2007","unstructured":"Roffey, S.J.; Obach, R.S.; Gedge, J.I.; Smith, D.A. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab. Rev. 2007,39(1),17-43. http:\/\/dx.doi.org\/10.1080\/03602530600952172 PMID: 17364879","journal-title":"Drug Metab.Rev"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/180287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T23:51:50Z","timestamp":1666137110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/180287\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,8,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620666200317105207","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}